Therapeutic agent for osteoporosis
To provide an agent for treating osteoporosis, comprising an acyl thiourea compound represented by the following formula (I) or a salt thereof as an active ingredient: wherein, R 1 represents an optionally substituted C 1-6 alkyl group; R 2 represents a fluorine atom or a chlorine atom; and R 3 represents a hydrogen atom, a fluorine atom, or a chlorine atom.
1. A method for treating osteoporosis, the method comprising administering a pharmaceutical composition comprising an acyl thiourea compound represented by formula (I) or a salt thereof and a pharmaceutically acceptable carrier to a patient in need thereof:
wherein,
R 1 represents an optionally substituted C 1-6 alkyl group, wherein a substituent is any one of a hydroxyl group, a C 3-10 cycloalkyl group, an optionally substituted C 1-6 alkoxy group, an optionally substituted C 1-6 alkylamino group, a C 1-6 alkanoylamino group, a C 1-6 alkylsulfonyl group, an optionally substituted C 6-14 aromatic hydrocarbon group, an optionally substituted saturated or unsaturated heterocyclic group, an optionally substituted C 1-6 alkylaminocarbonyl group, and an optionally substituted saturated or unsaturated heterocyclic carbonyl group;
R 2 represents a fluorine atom or a chlorine atom; and
R 3 represents a hydrogen atom, a fluorine atom, or a chlorine atom.
2. The method according to claim 1 , wherein the acyl thiourea compound is 4-[2-fluoro-4-[[[(2-phenylacety)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide monomethanesulfonate.